NEW YORK, Jan. 17, 2018 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Halozyme Therapeutics, Inc. ("Halozyme" or the "Company") (NASDAQ: HALO). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.
The investigation concerns whether Halozyme and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here to join a class action]
On January 16, 2018, an abstract detailing a Phase IB/II randomized study of Halozyme's drug PEGPH20 as a treatment for pancreatic cancer in combination with the cancer drug mFFOX was published in connection with a scheduled presentation at the 2018 Gastrointestinal Cancers Symposium. The abstract's authors concluded that the "addition of PEGPH20 to mFFOX is not recommended for further study and appears to be detrimental" after noting that patients who used the combination experienced higher levels of diarrhea, fatigue, nausea, vomiting, and more than those who used mFFOX as a monotherapy. Following this news, Halozyme's share price has fallen sharply during intraday trading on January 17, 2018.
The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.
CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
View original content:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-halozyme-therapeutics-inc--halo-300584095.html
SOURCE Pomerantz LLP
